Advanced pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine carcinomas (NECs)
Conditions
Brief summary
Overall survival (OS) in patients who received at least one dose of treatment.
Detailed description
Incidence, nature, and severity of treatment-related adverse events/treatment-emergent adverse events, graded according to the NCI CTCAE v5.0 except CRS and ICANS events graded using ASTCT 2019, Objective Response Rate (ORR), Duration of response (DoR), Disease Control Rate (DCR), Progression Free Survival (PFS), Overall Survival (OS), Quality of life of questionnaire EORTC QLQ-C30
Interventions
DRUGTarlatamab
DRUGOXALIPLATINE VIATRIS 5 mg/ml
DRUGDacarbazine "Lipomed"
DRUGTecentriq 1 200 mg concentrate for solution for infusion
DRUGTemozolomide 100 mg hard capsules
DRUGOPDIVO 10 mg/mL concentrate for solution for infusion.
DRUGKEYTRUDA 25 mg/mL concentrate for solution for infusion
DRUGTopotecan Accord Healthcare 4mg Powder for Concentrate for Solution for Infusion
DRUGsolution à diluer pour perfusion
Sponsors
Intergroupe Francophone De Cancerologie Thoracique
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival (OS) in patients who received at least one dose of treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence, nature, and severity of treatment-related adverse events/treatment-emergent adverse events, graded according to the NCI CTCAE v5.0 except CRS and ICANS events graded using ASTCT 2019, Objective Response Rate (ORR), Duration of response (DoR), Disease Control Rate (DCR), Progression Free Survival (PFS), Overall Survival (OS), Quality of life of questionnaire EORTC QLQ-C30 | — |
Countries
France
Outcome results
None listed